• Hyperactivity Disorder
    • Methylphenidate And...
    • Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder: Influence Statistics

      Expert Impact

      Concepts for whichthey havehas direct influence:Hyperactivity disorder,Adhd symptoms,Deficit hyperactivity,Attention deficit,Disorder hyperactivity,Disorder adhd,Extended release,Methylphenidate tablets.

      Key People For Hyperactivity Disorder

      Top KOLs in the world
      JOSEPH Biederman
      bipolar disorder attention deficit adults adhd
      Stephen V Faraone∗
      hyperactivity disorder attention deficit children adhd
      Thomas J Spencer
      hyperactivity disorder attention deficit adults adhd
      Russell A Barkley
      hyperactivity disorder attention deficit hyperactive children
      James M Swanson
      hyperactivity disorder children adhd attention deficit
      Jan K Buitelaar∗
      hyperactivity disorder attention deficit adhd symptoms

      Methylphenidate and dexmethylphenidate formulations for children with attention-deficit/hyperactivity disorder


      PURPOSE: Current literature on the safety and efficacy of various intermediate- and long-acting preparations of methylphenidate and dexmethylphenidate for pediatric attention-deficit/hyperactivity disorder (ADHD) is reviewed.

      SUMMARY: The efficacy of methylphenidate in controlling ADHD symptoms is firmly established. Given the drug's relatively short half-life in pediatric patients (about 2.5 hours), a number of intermediate- and long-acting products have been developed; these extended-release methylphenidate products provide the same efficacy as immediate-release (IR) formulations, with the convenience of less frequent dosing. Intermediate-acting methylphenidate preparations have effects lasting as long as 8 hours, but peak concentrations are not attained for up to 5 hours, and many patients may require twice-daily dosing. Long-acting methylphenidate products developed to address these challenges include a controlled-release tablet and bimodal-delivery capsules containing mixtures of IR and extended-release beads (durations of effect, 8-12 hours). Options for patients with difficulty swallowing tablets or capsules include a once-daily transdermal delivery system and a once-daily liquid formulation. Dexmethylphenidate (the more pharmacologically active d-isomer of racemic methylphenidate) can provide efficacy comparable to that of IR methylphenidate at half the dose; an extended-release form of dexmethylphenidate can provide less fluctuation in peak and trough concentrations than the IR form. Methylphenidate and dexmethylphenidate products in capsule form can be opened and sprinkled on applesauce.

      CONCLUSION: The various formulations of IR and intermediate- and extended-release methylphenidate and dexmethylphenidate can be useful options in satisfying patients' individual needs in the management of ADHD. All are equally efficacious in controlling ADHD symptoms.

      Sign-in to see all concepts, it's free!


    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.